Beckman Coulter Diagnostics, Brea, Calif, has announced the availability of the DxH 900 hematology analyzer. Company officials say the new analyzer enables high-resolution analysis of cells in their near-native states, providing a precise assessment of red blood cell, platelet, and white blood cell test results on the first pass, with minimal repeats.

“The DxH 900 hematology analyzer is an example of our commitment to the voice of the customer,” says Peter Soltani, PhD, senior vice president and general manager of the hematology business at Beckman Coulter. “We had over 100 of our customers view prototypes, and we enhanced our designs based on their input. Truly, the DxH 900 was designed by customers for customers.”

According to the company, the DxH 900 analyzer demonstrates 93% first-pass throughput, providing accurate flagging and reducing the number of slide reviews. Such first-pass efficiency helps to generate reportable results as quickly as possible, reducing the time, supplies, and costs that may be required for systems with higher repeat rates.

“The suite of technologies is intended to help laboratories deliver quality results for fast, accurate clinical decisionmaking,” says Soltani. “At the same time, the system includes automated solutions that streamline the number of procedural steps needed to produce those results, offering predictable performance and greater laboratory efficiency.”

The analyzer’s reagent portfolio employs four reagents instead of the 11 reagents required by other analyzers. Further, the DxH 900 features one of the smallest footprints in its class. Many of the parameters measured by the analyzer address critical health conditions, such as anemia, leukopenia, and thrombocytopenia. Beckman Coulter is also evaluating a hematology sepsis parameter that is part of a routinely ordered test in emergency departments.

For more information, visit Beckman Coulter Diagnostics.